Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Single-arm Phase 2 Study of Pembrolizumab and Lenvatinib in Previously Treated Inoperable or Advanced Anal Squamous Cell Cancer

NCT07680088 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT07680088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Single-arm Phase 2 Study of Pembrolizumab and Lenvatinib in Previously Treated Inoperable or Advanced Anal Squamous Cell Cancer
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2030
Enrollment
17 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma